Overview

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose of this treatment regimen.
Phase:
Phase 1
Details
Lead Sponsor:
Pediatric Brain Tumor Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Busulfan